Classement en actions
#5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Prix de l'action
$36.98
Dernière synchronisation: 2026-08-26
Capitalisation boursière
$2.58B
Changement (1 jour)
-0.67%
Échange Pharvaris N.V. (PHVS)
Le prix PHVS avec la capitalisation boursière de B
Capitalisation boursière de Pharvaris N.V.(PHVS)
Capitalisation boursière: $2.58B
En August 2026, Pharvaris N.V. a une capitalisation boursière de $2.58B. Cela fait de Pharvaris N.V. la 5577th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Pharvaris N.V. du 2021 au 2026
PHVS par rapport au top 5 des plus populaires stocks
| Prix pour PHVS |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.088T
|
+196,787.13%
|
|
|
|
|
$4.629T
|
+179,033.69%
|
|
|
|
|
$4.118T
|
+159,240.09%
|
|
|
|
|
$3.687T
|
+142,566.18%
|
|
|
|
|
$2.800T
|
+108,238.93%
|
